Cellab Cdmo
logo

Donation for research

  • Home
  •  
  • Donation for research

Donate biological material for scientific progress

At Cellab we are committed to biomedical research and since 2014 we have been working with the aim of improving people’s health, adding value through the production and development of stem cell therapies and treatments.

Cells and tissues are a scarce commodity and the only source of starting material for research and the production of advanced therapy drugs. For this very reason, many people decide to donate this material of high biological value for research in Andorra.

In recent years, thanks to these donations, many scientific and medical advances have been achieved that have helped many patients and have advanced basic research in the search for new treatments for diseases without care.

Legal framework

In accordance with the provisions of Law 3/2023, of 19 January, on biomedical research and innovation approved by the General Council, Cellab gives you the possibility to altruistically donate biological material such as blood and umbilical cord tissue, adipose tissue, peripheral blood, in order to use it for biomedical research.

Cellab also complies with Law 29/2021, of 28 October, on the protection of personal data, which guarantees the total confidentiality of the donor and of the biological sample data.

Cellab will never participate in research or clinical trials that have not been duly approved by the competent authorities. We therefore ensure that research carried out with the biological material of donors will have obtained the approval of the corresponding ethical committees.

laboratori recerca mèdica andorra
Recerca Andorra

How can you donate for research?

Participation in the research carried out by Cellab is completely voluntary and altruistic, as regulated by Andorran and European regulations. In order to participate, you must sign the informed consent form for donation for research, expressing your willingness to participate. You are free to revoke your consent at any time.

You can ask your doctor, the healthcare staff at the primary care centre or the hospital nursing staff for informed consent to be able to make the donation.

Cellab will be pleased to provide you with information about the research for which your donation of biological material has been used. You can find out more details by writing to info@cellab.com.

Clinical trials and active research where biological samples from donations are being sent

  • PHASE II CLINICAL TRIAL TO ESTABLISH THE SAFETY OF THE USE OF EXPANDED ALLOGENEIC FETAL UMBILICAL CORD STEM MESENCHYMAL STEM CELLS IN PRETERM PATIENTS WITH BRONCHOPULMONARY DYSPLASIA

Trial code: PULMESCELL-2
EudraCT No. 2022-002653-26.
Country of trial: Spain
Promoter of the study: Fundación para la Investigación Biomédica Hospital Ramón y Cajal
Principal Investigator: Dr. María Jesús del Cerro
Contact: mjesus.cerro@salud.madrid.org
Authorised since: 21-JUL-2023
Biological starting material: Umbilical Cord Tissue.
Short description of the trial: The efficacy and safety of mesenchymal cells from donor cord tissue (specifically Wharton’s Jelly) to improve lung development in premature infants weighing ≤ 1250 grams and gestational age ≤ 28 weeks, who are on mechanical ventilation between days 5 and 14 of life is studied. The development of these infants is assessed up to 24 months of age.
More detailed information about this clinical trial can be found at:
https://pulmescell2.org/index.php
https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002653-26/ES

  • ANALYSIS OF UMBILICAL CORD MESENCHYMAL STEM CELLS (UC-MSC) AS A POTENTIAL DRUG TARGETING FIBROTIC DIFFUSE INTERSTITIAL LUNG DISEASES (EPID).

ERC code: IB 5418/24 PI
Country where the trial is being conducted: Spain
Study Sponsor: Institute for Health Research of the Balearic Islands (IDISBA)
Principal Investigator: Ernest Sala Llinás
Contact: ernest.sala@ssib.es
Authorised since: 11-JAN-2024
Biological starting material: Umbilical Cord Tissue.
Short description of the trial: Idiopathic Pulmonary Fibrosis (IPF) is one of the most common, progressive diseases, of unknown cause and caused by a heterogeneity of factors that affect the pulmonary interstitium and the alveolar structures, causing an irreversible fibrosis and, consequently, an irreversible fibrosis.
fibrosis and, as a consequence, respiratory failure. In this context, experimental trials will be carried out to compare the therapeutic potential of mesenchymal cells in 2D (monolayer), 3D (biospheres) and 3De (encapsulated) cultures obtained from human umbilical cord. The results will determine the curative effect of MSCs and the most effective format for use in combating IPF.
More detailed information about this research and the sponsor can be found here:
https://www.idisba.es/es

  • MODIFIED AUTOLOGOUS MONONUCLEAR CELLS FOR THE TREATMENT OF ACUTE KIDNEY INJURY AFTER CARDIAC SURGERY 

Test code: M2R.AKI.2021
EudraCT No. 2023-504610-30-00.
Country where the trial is taking place: Spain
Study sponsor: M2rlab S.L.
Principal Investigator: Pablo García de la Riva Mestre
Contact: pgarciadelariva@m2rlab.com
Authorised since: Pending authorisation. Submitted on 29-JAN-2024
Biological starting material: Patient’s own peripheral blood.
Short description of the trial: Acute renal failure (ARF) following heart surgery with extracorporeal circulation is a serious disease with a poor prognosis. It involves inflammatory processes in the kidney that can lead to complete loss of kidney function and there are no therapies available to treat it. It is estimated that 12% of patients who have suffered acute renal failure require additional treatment with dialysis. M2RLab mononuclear cells are an advanced therapy drug that must be administered within 48 hours of kidney failure and is intended to be studied for efficacy and safety in this Phase II clinical trial.
More detailed information on this clinical trial can be found at:
https://m2rlab.com/m2r-technology/#THERAPY

  • DEVELOPMENT OF AN ALLOGENEIC GAMMA DELTA T-CELL PLATFORM FOR CANCER IMMUNOTHERAPY

Trial code: OC-3
IRB Code: CEIm-FJD Act No. 20/22 and Act No. 04/22
Country where the trial is taking place: Spain
Study Sponsor: OneChain Immunotherapeutics SL
Principal Investigator: Víctor Díaz Cortes
Contact: administracion@onechaintx.com
Approved since: 28/FEB/2023
Biological starting material: Umbilical cord blood
Short description of the trial: Development of a platform of allogeneic gamma delta T cells isolated from umbilical cord blood to develop different immunotherapy treatments against different types of cancer. Immunotherapy is being proposed as a superior alternative to standard cancer treatments such as chemotherapy or radiotherapy, showing better results and without the side effects associated with standard treatments. This platform would allow the development of much more affordable immunotherapies in terms of production costs and access to these therapies to a larger number of patients.
More detailed information about this research and its promoter can be found here:
https://www.onechaintx.com/

  • CELLCLI PROJECT

Country where the trial is taking place: Andorra
Study Sponsor: Cellab
Principal Investigator: Arnau Calvet
Contact: arnau.calvet@cellab.com
Approved since: 19/09/2024
Biological starting material:  Umbilical cord tissue and adipose tissue
Short description of the trial: This doctoral research is part of the CELLCLI project, focused on developing a new cellular therapy to treat Critical Limb Ischemia (CLI), a severe manifestation of Peripheral Arterial Disease (PAD). CLI leads to reduced blood flow in the lower extremities, causing pain, tissue necrosis, and a high risk of amputation. Current treatments, including surgical interventions, often fail, highlighting the need for innovative therapies, as advanced therapies, specifically, cell therapy.
The project explores the use of preconditioned human mesenchymal stem cells (hMSCs) derived from adipose tissue (AT) and umbilical cord tissue (UCT) as a potential allogeneic therapy. Preconditioning hMSCs with chemical, pharmacological or physical agents, is hypothesized to enhance their proangiogenic and immunomodulatory properties, thus improving tissue revascularization and reducing inflammation. The research involves detailed in vitro and in vivo assays to characterize the safety and therapeutic potential of preconditioned hMSCs for CLI. This research aims to optimize cell culture conditions, identify key secreted factors, and assess the efficacy of preconditioned hMSCs to offer better outcomes for CLI patients.

  • CELLULAR THERAPY IN THE TREATMENT OF ANDROGENETIC ALOPECIA

Trial code: AGACELL-19 (Registration code: ES280790000088)
Eudra CT No.: Pending
Country where it takes place: Spain
Study promoter: Idea Stem Cell SL
Principal investigator: Eduardo Lopez-Bran
Contact: joseangelsanchez@ideastemcell.com
Authorized since: 06/16/2020
Biological starting material: Adipose tissue
Brief description of the trial: Cellular therapy in the treatment of androgenetic alopecia through the use of expanded mesenchymal stem cells derived from adipose tissue.

Call us for more information

Or you can send us a message here

© 2021
Cellab Cdmo

© 2021 Cellab - Regenerative therapies for family health